Clinical trial
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder
NCT01972841 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder
- Lead sponsor
- Astellas Pharma Europe B.V.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 5, 2013
- Completion date
- October 22, 2015
- Enrollment
- 3,527 (actual)
- Sites
- 435
Conditions
As the registry lists them; a condition with its own page is linked.
overactive bladder, urgency incontinence, urinary bladder diseases\urologic diseases, urinary bladder overactive